Tandem Diabetes Care Inc. has developed the t:slim insulin pump delivery system combing the first touch-screen pump and a therapy management software called t:connect. The company began shipping the U.S. Food and Drug Administration-cleared device in late August. It comes with a USB port and cable that can transfer data captures in the device to any Internet-enabled Mac or PC.
Company name: Tandem Diabetes Care Inc.
Industry: health IT/medical devices
Location: San Diego, California.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Money raised: $36.4 million of $50 million goal.
How it will be used: The money will be used to expand the company’s sales and marketing capacity. It will also be used to fund customer support systems and in research and development, said a company spokesman
Investors: Domain Associates, Delphi Ventures, TPG Biotechnology, HLM Venture Partners, Howard Greene Jr. and John Livingston.
Market opportunity: The global diabetes device market is projected to grow to $25.3 billion, up from $17.7 billion last year. A spokesman for Tandem Diabetes said the U.S. insulin pump market is $1.5 billion, but only one-third of type 1 diabetes patients use an insulin pump, which represents a significant opportunity for the company.
Competitors: Medtronic, Johnson & Johnson and Roche.